den Brok Martijn H M G M, Nierkens Stefan, Figdor Carl G, Ruers Theo J M, Adema Gosse J
Department of Tumor Immunology, Nijmegen Centre for Molecular Life Sciences, Radboud University Medical Centre, 6500 HB Nijmegen, The Netherlands.
Expert Rev Vaccines. 2005 Oct;4(5):699-710. doi: 10.1586/14760584.4.5.699.
Dendritic cells are the most potent antigen-presenting cells of the immune system and represent a promising tool in therapeutic vaccination against cancer. Immunotherapy applying ex vivo-generated and tumor antigen-loaded dentritic cells has been successfully introduced in clinical vaccination protocols and has proven to be feasible and effective in some patients. A better understanding of how dentritic cells succeed to induce and modulate immunity is necessary to optimally exploit dentritic cells in anticancer vaccines. The authors will review novel insights in antigen loading, activation and migration of dentritic cells and their impact on the application of ex vivo-generated dentritic cell vaccines. In addition, novel means to exploit dentritic cells in cancer vaccines by loading and activation of dentritic cells directly in situ and possible obstacles that should be overcome to induce long-lasting immunity in therapeutic settings will be discussed.
树突状细胞是免疫系统中最强大的抗原呈递细胞,是癌症治疗性疫苗接种中一种很有前景的工具。应用体外生成并负载肿瘤抗原的树突状细胞进行免疫治疗已成功应用于临床疫苗接种方案,并已在一些患者中证明是可行且有效的。为了在抗癌疫苗中最佳地利用树突状细胞,有必要更好地了解树突状细胞如何成功诱导和调节免疫。作者将综述树突状细胞抗原负载、激活和迁移方面的新见解及其对体外生成的树突状细胞疫苗应用的影响。此外,还将讨论通过直接在原位负载和激活树突状细胞在癌症疫苗中利用树突状细胞的新方法,以及在治疗环境中诱导持久免疫应克服的可能障碍。